No Data
No Data
These 4 Measures Indicate That Shandong Weigao Group Medical Polymer (HKG:1066) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
From the pain of collection to the decline in net profit distribution, going overseas or becoming the only way out for orthopedic consumables?
As the fourth batch of high-value consumables collected last year directly targeted artificial lenses and high-value orthopedic sports medicine consumables, almost all high-value consumables in the orthopedic field have already been collected. Even if this collection is “mild” compared to the previous three rounds of overall price cuts, it will inevitably have a negative impact on the performance of leading domestic companies in the short term, and there is a certain relationship with the imbalance in the companies' “price for volume” game. Judging from the 2023 financial reports disclosed by many industry companies, the traditional logic of “price for volume” collection has not been fully demonstrated. It is not that the more companies that win the bid, the better their performance growth. On the contrary, the increase in sales brought about by harvesting does not seem to offset the product
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Bank Rating | DBS: Lowering the target price of Weigao shares to HK$6.4 to maintain a “buy” rating
According to a research report published by DBS, the profit of Weigao shares fell 27.6% year-on-year in 2023, in line with the profit announcement issued earlier, mainly due to falling prices of medical devices and consumables products in different businesses due to volume procurement policies, and no longer selling products related to the epidemic. Accordingly, DBS lowered Weigao's profit forecast for 2024 to 2025 by 32% and 35%, and the target price was lowered from HK$11.6 to HK$6.4. However, the bank pointed out that Weigao's stock price has fallen 37% a few years ago. The expected negative factors are fully reflected in the stock price performance. It is optimistic that the company is the leading supplier of medical consumables and pharmaceutical packaging in China
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 36% over the past three months, it is easy to disregard Shandong Weigao Group Medical Polymer (HKG:1066). But if you pay close attention, you might find that its key financial in
Changes in Hong Kong stocks | Medical device stocks rose higher in the afternoon, and mining affected the industry's high-value consumables business growth expectations this year generally improved
Medical device stocks rose in the afternoon. As of press release, Weigao shares (01066) rose 9.25% to HK$5.08; Elken Healthcare (01,789) rose 4.35% to HK$4.08; and minimally invasive robot-B (02252) rose 1.91% to HK$13.88.
No Data